Shawn Langer Acquires Common Shares of Vaxil Bio Ltd.
06 févr. 2018 16h32 HE
|
Shawn Langer
TORONTO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Shawn Langer announces that on January 26, 2018, he acquired (the "Acquisition") by way of private placement ownership over 4,985,000 units ("Units") of...
Ari Kellen Acquires Common Shares of Vaxil Bio Ltd.
05 févr. 2018 17h49 HE
|
Ari Kellen
TORONTO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Ari Kellen announces that on January 26, 2018, he acquired (the "Acquisition") by way of private placement ownership over 4,985,000 units ("Units") of...
Vaxil Completes Oversubscribed Financing to Advance Its Cancer Immunotherapy Research and Development
30 janv. 2018 08h30 HE
|
Vaxil Bio Ltd.
NESS-ZIONA, ISRAEL--(Marketwired - January 30, 2018) - VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli cancer immunotherapy company, is pleased to announce the closing of an oversubscribed...
Vaxil Strengthens Board of Directors and Management Concurrent to $1-Million Financing
05 déc. 2017 08h30 HE
|
Vaxil Bio Ltd.
NESS-ZIONA, ISRAEL--(Marketwired - December 05, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli immuno-oncology biotechnology company, is pleased to announce the addition of two...
Cancer Immunotherapy Company Vaxil Appoints Dr. Terry Plasse as Chief Medical Officer
24 juil. 2017 08h30 HE
|
Vaxil Bio Ltd.
TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - July 24, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli-Canadian biotech developing innovative immunotherapy treatments for cancer, is pleased...
Vaxil Launches Manufacturing of ImMucin Immunotherapy for Upcoming Clinical Trials
23 mai 2017 08h30 HE
|
Vaxil Bio Ltd.
TORONTO, ON, and NESS ZIONA, ISRAEL--(Marketwired - May 23, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), a biopharmaceutical company focused on developing immunotherapies based on signal peptides from...
Vaxil Announces Novel Immunotherapy Poster Presentation at 2017 American Association for Cancer Research Meeting
03 mars 2017 08h00 HE
|
Vaxil Bio Ltd.
NESS ZIONA, ISRAEL and TORONTO, ON--(Marketwired - March 03, 2017) - Vaxil Bio Ltd. ("Vaxil", or the "Company") (TSX VENTURE: VXL) is pleased to announce that the Company's abstract illustrating...
Vaxil to Present at BIO CEO & Investor Conference
09 févr. 2017 09h30 HE
|
Vaxil Bio Ltd.
NESS-ZIONA, ISRAEL and TORONTO, ON--(Marketwired - February 09, 2017) - Vaxil Bio Ltd. ("Vaxil", or the "Company") (TSX VENTURE: VXL) today announces its participation in the Annual BIO CEO and...
Vaxil Bio Expands Into Infectious Diseases With First US Patent for MTbuVax(TM)
19 janv. 2017 09h30 HE
|
Vaxil Bio Ltd.
TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - January 19, 2017) - VAXIL BIO (TSX VENTURE: VXL), a biotech specializing in immunotherapy, announces today that it has received an important Notice of...
Vaxil Bio Research Coverage and Inclusion in the List of Key Players in Immuno-Oncology
04 janv. 2017 18h00 HE
|
Vaxil Bio Ltd.
TORONTO, ON and NESS-ZIONA, ISRAEL--(Marketwired - January 04, 2017) - Vaxil Bio Ltd. (TSX VENTURE: VXL) -- Following Vaxil's recent announcement that it had received encouraging preliminary results...